FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2530081471> ?p ?o ?g. }

• W2530081471 endingPage "220" @default.
• W2530081471 startingPage "209" @default.
• W2530081471 abstract "The present study focuses on the development of dry powders for inhalation as adjuvant chemotherapy in lung cancer treatment. Cisplatin was chosen as a potential candidate for a local treatment as it remains the main platinum component used in conventional chemotherapies, despite its high and cumulative systemic toxicities. Bulk cisplatin was reduced to submicron sizes using high-pressure homogenization, mixed with a solubilized lipid and/or PEGylated component and then spray-dried to produce controlled-release dry powder formulations. The obtained formulations were characterized for their physicochemical properties (particle size and morphology), aerodynamic performance and release profiles. Cisplatin content and integrity were assessed by electrothermal atomic absorption spectrometry and 195Pt nuclear magnetic resonance spectroscopy. DPI formulations with cisplatin contents ranging from 48.5 to 101.0% w/w exhibited high fine particle fractions ranging from 37.3% to 51.5% of the nominal dose. Formulations containing cisplatin microcrystals dispersed in solid lipid microparticles based on acceptable triglycerides for inhalation and PEGylated excipients showed a controlled-release for more than 24h and a limited burst effect. These new formulations could provide an interesting approach to increasing and prolonging drug exposure in the lung while minimizing systemic toxicities." @default.
• W2530081471 created "2016-10-21" @default.
• W2530081471 creator A5001570029 @default.
• W2530081471 creator A5016360559 @default.
• W2530081471 creator A5023639152 @default.
• W2530081471 creator A5042790280 @default.
• W2530081471 creator A5047176016 @default.
• W2530081471 creator A5049768102 @default.
• W2530081471 creator A5072578982 @default.
• W2530081471 date "2016-12-01" @default.
• W2530081471 modified "2023-10-14" @default.
• W2530081471 title "Development of controlled-release cisplatin dry powders for inhalation against lung cancers" @default.
• W2530081471 cites W1483471069 @default.
• W2530081471 cites W1552667652 @default.
• W2530081471 cites W1757407923 @default.
• W2530081471 cites W1974908685 @default.
• W2530081471 cites W1975727847 @default.
• W2530081471 cites W1980411311 @default.
• W2530081471 cites W1986805054 @default.
• W2530081471 cites W1987751216 @default.
• W2530081471 cites W1988087430 @default.
• W2530081471 cites W2004931777 @default.
• W2530081471 cites W2020130442 @default.
• W2530081471 cites W2021072600 @default.
• W2530081471 cites W2022173743 @default.
• W2530081471 cites W2023302396 @default.
• W2530081471 cites W2042600528 @default.
• W2530081471 cites W2043610941 @default.
• W2530081471 cites W2050497527 @default.
• W2530081471 cites W2050569993 @default.
• W2530081471 cites W2051011112 @default.
• W2530081471 cites W2065680155 @default.
• W2530081471 cites W2085051997 @default.
• W2530081471 cites W2085973450 @default.
• W2530081471 cites W2099744262 @default.
• W2530081471 cites W2108677865 @default.
• W2530081471 cites W2115439624 @default.
• W2530081471 cites W2127618819 @default.
• W2530081471 cites W2140442968 @default.
• W2530081471 cites W2157274368 @default.
• W2530081471 cites W2157365457 @default.
• W2530081471 cites W2167310101 @default.
• W2530081471 cites W2169884947 @default.
• W2530081471 cites W4231439411 @default.
• W2530081471 cites W4233976617 @default.
• W2530081471 doi "https://doi.org/10.1016/j.ijpharm.2016.10.019" @default.
• W2530081471 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27737810" @default.
• W2530081471 hasPublicationYear "2016" @default.
• W2530081471 type Work @default.
• W2530081471 sameAs 2530081471 @default.
• W2530081471 citedByCount "44" @default.
• W2530081471 countsByYear W25300814712017 @default.
• W2530081471 countsByYear W25300814712018 @default.
• W2530081471 countsByYear W25300814712019 @default.
• W2530081471 countsByYear W25300814712020 @default.
• W2530081471 countsByYear W25300814712021 @default.
• W2530081471 countsByYear W25300814712022 @default.
• W2530081471 countsByYear W25300814712023 @default.
• W2530081471 crossrefType "journal-article" @default.
• W2530081471 hasAuthorship W2530081471A5001570029 @default.
• W2530081471 hasAuthorship W2530081471A5016360559 @default.
• W2530081471 hasAuthorship W2530081471A5023639152 @default.
• W2530081471 hasAuthorship W2530081471A5042790280 @default.
• W2530081471 hasAuthorship W2530081471A5047176016 @default.
• W2530081471 hasAuthorship W2530081471A5049768102 @default.
• W2530081471 hasAuthorship W2530081471A5072578982 @default.
• W2530081471 hasConcept C141071460 @default.
• W2530081471 hasConcept C147789679 @default.
• W2530081471 hasConcept C181389837 @default.
• W2530081471 hasConcept C185592680 @default.
• W2530081471 hasConcept C187530423 @default.
• W2530081471 hasConcept C192562407 @default.
• W2530081471 hasConcept C2776694085 @default.
• W2530081471 hasConcept C2776954882 @default.
• W2530081471 hasConcept C2778239845 @default.
• W2530081471 hasConcept C42219234 @default.
• W2530081471 hasConcept C43617362 @default.
• W2530081471 hasConcept C71924100 @default.
• W2530081471 hasConcept C77281830 @default.
• W2530081471 hasConcept C98274493 @default.
• W2530081471 hasConceptScore W2530081471C141071460 @default.
• W2530081471 hasConceptScore W2530081471C147789679 @default.
• W2530081471 hasConceptScore W2530081471C181389837 @default.
• W2530081471 hasConceptScore W2530081471C185592680 @default.
• W2530081471 hasConceptScore W2530081471C187530423 @default.
• W2530081471 hasConceptScore W2530081471C192562407 @default.
• W2530081471 hasConceptScore W2530081471C2776694085 @default.
• W2530081471 hasConceptScore W2530081471C2776954882 @default.
• W2530081471 hasConceptScore W2530081471C2778239845 @default.
• W2530081471 hasConceptScore W2530081471C42219234 @default.
• W2530081471 hasConceptScore W2530081471C43617362 @default.
• W2530081471 hasConceptScore W2530081471C71924100 @default.
• W2530081471 hasConceptScore W2530081471C77281830 @default.
• W2530081471 hasConceptScore W2530081471C98274493 @default.
• W2530081471 hasIssue "1-2" @default.
• W2530081471 hasLocation W25300814711 @default.
• W2530081471 hasLocation W25300814712 @default.
• W2530081471 hasOpenAccess W2530081471 @default.

• next